# Hypothalamus and adenohypophysis



#### Ventrolateral medulla (heart, stomach)

Amygdala (associative regions of neocortex, olfactory bulb, hippocampal formation, subcortical structures including brain stem)

Hippocampus (associative regions of neocortex, thalamus, reticular formation nuclei, etc.)

#### Nucleus solitarius

(viscerosensory information– heart, lungs, GIT, blood vessels – baro-/chemoreceptors)

#### Orbitofrontal cortex

(sensory perception, reaction to reward/punishment)

## Hypothalamus

Locus coeruleus (prefrontal cortex, N. paragigantocellularis – integration of external and autonomic stimuli – stress, panic)

Lamina terminalis (blood, blood composition)

#### **Behavior**

Body temperature regulation

Neuroendocrine regulation

Appetitive behavior (hunger, thirst, sexual behavior)

**Defensive reactions** 

Biorhythms and their regulation

Autonomic nervous system (modulation)

## Circumventricular organs

#### Eminentia mediana

- Afferent sensoric organ
- Functional connection of hypothalamus and hypophysis
- Point of entry of some hormones from circulation (fenestration) leptin
- CONVERSION HUMORAL FACTORS HYPOTHALAMIC REGULATION NEURONS

#### OVLT


- Regulation of autonomous processes
- Febrile regulation
- Blood osmolality
- Regulation of secretion of GnRH stimulated by estrogens

#### Area postrema

- Afference (n. vagus, n. glossopharyn-geus)
- R for GLP-1 and amylin
- Chemosensoric neurons with osmoR
- detection" of toxins
- coordinated regulation of blood pressure (R for ATII, ADH, ANP)

#### Subfornical organ

- Body fluid homeostasis
- Blood pressure regulation (R for ANP and ATII)
- Oxytocin secretion regulation





#### Subcommissural organ

- Mainly unknown function
- R for neuropeptides and neurotransmitters
- ? Production of somatostatin
- "catching" of monoamines from CSF

CC – corpus calosum OC – chiasma opticum ac – commisura anterior pc – commisura posterior AP – area postrema CP – choroid plexus ME – eminentia mediana NH – neurohypophysis OVLT – organum vasculosum laminae terminalis PI – pineal gland/epiphysis SCO – subcommissural organ SFO – subfornical organ

# Anatomical and functional connection of hypothalamus and hypophysis, neuroendocrine secretion






## Hypothalamic hormones

Hypothalamic hormones are secreted in eminentia mediana region and enter portal circulation via fenestrations

Axons of oxytocin and ADH synthesizing neurons go through eminentia mediana region. Hormones are secreted in neurohypophysis

PIH (prolactin-inhibiting hormone) = dopamine

Environmental factors Neural stimuli Hormonal stimuli




| Vasopressiii                                                                                                                                                                                                          |  |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| <i>Cys</i> -Tyr-Phe-Gln-Asn- <i>Cys</i> -Pro-Arg-Gly-NH₂ (MW = 1084.38)                                                                                                                                               |  |  |  |
| Oxytocin                                                                                                                                                                                                              |  |  |  |
| Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂ (MW = 1007.35)                                                                                                                                                                |  |  |  |
| Thyrotropin-Releasing Hormone                                                                                                                                                                                         |  |  |  |
| $pGlu-His-Pro-NH_2$ (MW = 362.42)                                                                                                                                                                                     |  |  |  |
| Gonadotropin-Releasing Hormone                                                                                                                                                                                        |  |  |  |
| pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH <sub>2</sub> (MW = 1182.39)                                                                                                                                               |  |  |  |
| Corticotropin-Releasing Hormone                                                                                                                                                                                       |  |  |  |
| Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-<br>Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-<br>Ile-NH <sub>2</sub> (MW = 4758.14)            |  |  |  |
| Growth Hormone-Releasing Hormone                                                                                                                                                                                      |  |  |  |
| Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-<br>Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-<br>Arg-Ala-Arg-Leu-NH <sub>2</sub> (MW = 5040.4) |  |  |  |
| Somatostatin                                                                                                                                                                                                          |  |  |  |
| Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (MW = 1638.12)                                                                                                                                                |  |  |  |
| Vasoactive Intestinal Peptide                                                                                                                                                                                         |  |  |  |
| His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-<br>Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH <sub>2</sub> (MW = 3326.26)                                                                    |  |  |  |

Vacoproscip

#### Signal integration to regulate endocrine functions and to maintain hoemeostasis

## Adenohypophyseal hormones




Physiological effect homeostasis maintainance

## Adenohypophysis

| - ACTH | _ | adrenocorticotropic hormone   |
|--------|---|-------------------------------|
| - TSH  | — | thyroid-stimulating hormone   |
| - GH   | - | growth (somatotropic) hormone |
| - PRL  | - | prolactin                     |
| - LH   | — | luteinizing hormone           |
| - FSH  | _ | follicle-stimulating hormone  |
|        |   |                               |

| Adenohypophyseal<br>cells | Represent<br>ation | Hypothalamic<br>hormone(s) | Adenohypophyseal<br>hormones                                | Localization          |
|---------------------------|--------------------|----------------------------|-------------------------------------------------------------|-----------------------|
| Lactotropic               | Up to 25 %         | Dopamine                   | prolactin                                                   | whole AH              |
| Corticotropic             | Ca 20 %            | CRH                        | POMC – ACTH, $\beta$ -<br>LPH, $\alpha$ -MSH, $\beta$ -end. | Anteromedial region   |
| Thyreotropic              | Ca 5 %             | TRH                        | TSH                                                         | Anteromedial region   |
| Gonadotropic              | Up to 15 %         | GnRH                       | LH/FSH                                                      | Posterolateral region |
| Somatotropic              | Ca 40 %            | GHRH/GHIH                  | GH                                                          | Posterolateral region |

#### HORMONE PRODUCTION UNDER DIRECT HYPOTHALAMIC CONTROL



## Axis GHRH/GHIH-GH-IGF-1

## Somatoliberin, (GHIH, growth hormone-releasing hormone)

#### Characteristics

- Two types present in hypothalamus
- GHRH receptor (cAMP)
- R homology with R secretin, GLP-1, glucagon, calcitonin, PTH, PTHrP

#### Hypothalamo-hypophyseal axis

- Fast GH secretion
- + estrogens, glucocorticoids and starvation
- - Somatostatin, age and obesity

#### **Clinical significance**

Nowadays without clinical significance
 GHRP

#### **Regulation of secretion**

- stimulation
  - Ghrelin
  - Leptin
  - Galanin
  - GABA
  - $\alpha$ 2-adrenergic and dopaminergic input
- inhibition
  - CRH
  - $-\beta$ 2-adrenergic input

### Somatostatin (GHIH, growth hormone-inhibiting hormone)

Characteristics

- Neurotransmitter – neuromodulator

Hypothalamo-hypophyseal axis

- GH secretion regulation
- TSH inhibition
- PRL and ACTH secretion inhibition

Clinical significance

- Somatostatin analogues (octreotide, lanreotide, vapreotide, seglitide, pasireotide)
- Therapy of acromegaly, TSH producing or neuroendocrine tumors
- ! Negative GIT side effects
- Imaging methods (<sup>111</sup>In-somatostatin)
- Potential use in tumor treatment

## Main effects of somatostatin

| Inhibition of hormone secretion                           | GIT inhibition                                              | Other                                         |
|-----------------------------------------------------------|-------------------------------------------------------------|-----------------------------------------------|
| Adenohypophysis – TSH, GH, ACTH, PRL                      | Stomach and duodenal secretion including HCI                | Inhibition of activated immune cells          |
| GIT – gastrin, secretin, motilin, GLP-1,<br>GIP, VIP      | Stomach emptying                                            | Inhibition of tumor growth<br>(proliferation) |
| Endocrine pancreas – insulin, glucagon,<br>(somatostatin) | Pancreatic enzymes and bicarbonates secretion               |                                               |
| Kidneys - renin                                           | Bile secretion                                              |                                               |
|                                                           | Decrease of GIT blood flow                                  |                                               |
|                                                           | Stimulation of intestinal water and electrolytes absorption |                                               |

## Growth hormone (GH)

Characteristics

- -hGH genome 5 products including human chorionic somatomammotropin
- -hGH-N somatotrophs 20/22 kDA
- -hGH-V placenta feedback regulation

-Circulating GH:


- 20 (25 %) and 22 kDA (75 %) monomers
- Acetylated 22 kDA form
- Deaminated forms

Regulation of secretion

-GHRH, somatostatin, ghrelin, IGF-1, thyroid hormones, glucocorticoids

-Relatively complicated system of regulation based on:


- Neuropeptides
- Neurotransmitters
- Endogenic opioids



## Growth hormone (GH) – regulation of secretion

- GHRH (continual), somatostatin (pulsatile secretion)
- Desensitization of R for GHRH
- IGF-1 somatostatin
- Ghrelin
  - GHS receptors stimulation of GHRH secretion
  - Synthesis stomach and CNS, regulation of food intake
- Diurnal rhythm with maximum during sleep (first episode of slow-wave sleep)
- Very low basal secretion, decrease with age (peak in puberty, then decrease)

| Interval                          | Young<br>Adult | Fasting       | Obesity | Middle<br>Age |
|-----------------------------------|----------------|---------------|---------|---------------|
| 24-h secretion ( $\mu g/24 h$ )   | 540 ± 44       | 2171 ±<br>333 | 77 ± 20 | 196 ± 65      |
| Secretory bursts (number in 24 h) | 12±1           | 32 ± 2        | 3±0.5   | 10 ± 1        |
| GH burst (μg)                     | 45 ± 4         | 64 ± 9        | 24 ± 5  | 10 ± 6        |



## Stimulation of GH secretion - overview

| Physiological factors             | Hormones and neurotransmitters                                                                                       | Pathological factors         |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------------|------------------------------|
| Exercise                          | Arginin, lysin                                                                                                       | Acromegaly                   |
| Stress (various causes)           | Neuropeptides (ghrelin, GHRH,<br>galanin, opioids – μ receptors,<br>melatonin)                                       | TRH, GnRH                    |
| Sleep                             | Neurotransmitters (agonists $\alpha$ 2-AR,<br>antagonists $\beta$ -AR, M1 agonists, 5-HTD1<br>agonists, H1 agonists) | Glu, Arg                     |
| Decrease in postprandial glycemia | GABA                                                                                                                 | IL-1, 2, 6                   |
| Starvation                        | Dopamine (D2R)                                                                                                       | Protein depletion            |
| Insulin-induced hypoglycemia      | Estrogens                                                                                                            | Starvation, anorexia nervosa |
|                                   | Testosterone                                                                                                         | Kidney failure               |
|                                   | Glucocorticoids (acute, not chronic)                                                                                 | Liver cirrhosis              |
|                                   |                                                                                                                      | DM 1st type                  |

## Inhibition of GH secretion

| Physiological factors                        | Hormones and neurotransmitters                                                                                                                                             | Pathological factors |
|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Postprandial hyperglycemia, glucose infusion | Somatostatin                                                                                                                                                               | Acromegaly           |
| Increased FAA in plasma                      | Calcitonin                                                                                                                                                                 | L-DOPA               |
| Increased GH concentration in plasma         | Neuropeptide Y                                                                                                                                                             | D2R agonists         |
| Increased IGF-1 concentration in plasma      | CRH                                                                                                                                                                        | Phentolamin          |
| REM sleep                                    | Neurotransmitters ( $\alpha$ 1,2-AR<br>antagonists, $\beta$ -AR agonists, H1<br>antagonists, serotonin receptor<br>antagonists, nicotine cholinergic<br>receptor agonists) | Galanin              |
| Aging                                        | Glucocorticoids (chronic)                                                                                                                                                  | Obesity              |
|                                              |                                                                                                                                                                            | Hypothyroidismus     |
|                                              |                                                                                                                                                                            | Hyperthyroidismus    |

## GH and interaction with other hormonal axes

ACTH – Glucocorticoids

- Acute (+) effect after ca 3 hours
- Chronic (-)

#### TRH – TSH – thyroid hormones

- Necessary for GH secretion
- Hypothyroidismus (-)

#### GnRH – FSH a LH – sex hormones

- Testosterone (+)
- Estrogens (+) only p.o. decreased inhibition of IGF-1 + feedback
- aromatization of androgens affects GH synthesis and secretion (paracrine effect of estrogens in CNS)

## GH and its effects

#### **METABOLIC**

-Energetic metabolism

-Together with insulin (metabolism of sugars, fats, proteins)
-Lipolysis and FA oxidation(+) (hormone-sensitive lipase, + LDL)
-Glucose – direct or indirect effect,


- (+) uptake of Glu
- (-) Glu oxidation
- (+) gluconeogenesis

#### -Proteins

- (+) anabolism, (-) urea
- (+) AA transport
- (+) incorporation of AA to proteins
- (-) protein oxidation

#### GROWTH

-Mediated by IGF-1 (auto-/paracrine)



### GH – clinical aspects

**GH deficiency** – gained or congenital – often tumors or inflammation

- nonspecific symptoms (i.e. loss of energy, social isolation, loss of focus)
- myocardium changes (left ventricle)

#### **GHR** – mutation

Significance of markers (IGF-1, IGFBP3)

**Substitution therapy** – wide array of side-effects, contraindication – cancer

#### **Experimental indications:**

- catabolic states (i.e. extensive burns)
- osteoporosis
- HIV/AIDS
- sport medicine, aging





## **Axis PIH-prolactin**

## PIH, prolactin-inhibiting hormone

#### Characteristics

- dopamine

#### Hypothalamo-hypophyseal axis

- Inhibition of PRL (D2R) secretion lactotropic cells
- ! Lactotrophs with continual high PRL production
- Paracrine and autocrine regulation of PRL secretion

#### Other functions and places of synthesis

- Blood vessels vasodilatation (physiological concentrations)
- Kidneys sodium secretion
- Endocrine pancreas decrease in insulin secretion
- GIT lower motility
- Effect of dompamine on immune system

#### **Clinical significance**

- Effect of medication on dopamine and PRL secretion
- Neurodegenerative diseases (Parkinson)
- Antipsychotics (antag.)

#### PROLACTIN-RELEASING FACTORS (PRF)

- TRH, oxytocin, VIP
- under specific conditions ADH, ATII, NPY, galanin, substance P, GRP, neurotensin
- prolactin-releasing peptide (PrRP) –
   stress, satiety (other parts of CNS)
- Important feedback mechanism (short loop) of PRL secretion regulation
  - Circadian rhythm (maximum in the morning)
  - Nipple stimulation (1-3 min, peak 10 20 min)


## Prolactin - PRL

#### Characteristics

- Lactotropic cells (only PRL)
- Mammosomatotropic cells (PRL and GH)
- Hyperplasia pregnancy and lactation
- Expression regulated by estrogens, dopamine, TRH, thyroid hormones
- PRLR mammary gl., adenohypophysis, adrenal gl., liver, prostate, ovaries, testicles, small intestine, lungs, myocardium, SNS, lymphocytes

#### Regulation of secretion

- Pulsatile secretion 4 14 pulses/day
- Highest levels during sleep (REM, nonREM)
- Lowest between 10:00 and 12:00
- Lower secretion with aging
- TIDA cells dopamine Paracrine endothelin-1, TGF-β1, calcitonin, histamine (-)
- FGF, EGF (+)
- TRH, estrogens, VIP, serotonin, GHRH in higher concentrations (+)
- Cholecystokinin ?



## Prolactin - functions

Production of breast milk during pregnancy and lactation = function necessary for survival

Other functions – metabolic, melatonin synthesis, maternal behavior

Development of mammary gland and lactation

- Puberty development of mammary gland due to GH and IGF-1
- Effect of estrogens and progesterone
- At age 8 13
- During pregnancy proliferation of alveoli and production of breast milk proteins and colostrum
- During third trimester colostrum production (PRL, estrogens, progesterone, GH, IGF-1, placental hormones)
- Lactation increase of PRL after birth, without breastfeeding decrease after ca 7 days
- Accumulation of breast milk stops further productionRole of OT

Reproductive function of PRL

- Lactation = amenorrhea and secondary infertility
- Inhibition of GnRH secretion
- Role of kisspeptin neurons (PRLR)
- Possible role of metabolic factors

#### Immune function of PRL

- Antiinflammatory effect ?

#### **Clinical significance**

- hyperprolactinemia drugs including some antihypertensives, chronic kidney failure
- Macroprolactinemia
- Galactorrhea role of GH (acromegaly)
- PRL deficiency

## Axis GnRH-LH/FSH-gonads

## GnRH, Gonadotropin-Releasing Hormone, GnIH

#### Characteristics


- Specific origin of GnRH neurons outside of CNS
- Downregulation malnutrition, lactation, seasonal effects, aging, continual GnRH
- Upregulation effect of GnRH on gonadotrophs (menstrual cycle)

#### Hypothalamo-hypophyseal axis

- FSH, LH
- Importance of GnRH pulses frequency (glycosylation)
- Menstrual cycle, puberty and its onset

#### **Clinical significance**

- Continually distributed analogues of GnRH – treatment of estrogen/steroid-dependent tumors of reproductive system
- Premature puberty treatment (leuprorelin – agonist!)



#### **Regulation of secretion**

- Inputs from various CNS regions (brain stem, limbic system)
- Inhibitory effect of sex-hormones with exception of estradiol (negative/positive feedback)
- Importance of kisspeptin for femalesInhibitory effect of PRL
- Effect of circulating substrates (FA, Glu)
- Leptin (NPY, kisspeptin)

#### - Stress (various causes)

- Acute disruption of MC without effect on fertility
- Chronic disruption of fertility, lowering of circulating sex-hormones levels


## GnIH, Gonadostatin

#### **Characteristics**

- Discovered in 2000
- Dorsomedial nucleus of the hypothalamus
- Projection to the eminentia mediana
- Binding to GnIH receptor (hypothalamus, adenohypophysis, ovary)
- Differential secretion during the ovarian cycle

#### **Functions**

- Regulation of the reproduction axis, including the onset of puberty
- Regulation of the reproduction behaviour
- Regulation of some CNS functions (neurotransmitter synthesis)




## Glycoproteins – FSH a LH

Characteristics

- Heterodimer, different expression of subunits, glycosylation
- Structurally close to hCG (placenta)

Regulation of secretion

- sex hormones, local factors paracrine (activins, inhibins, follistatin)
- (+) glutamate, noradrenaline, leptin
- (-) GABA, opioids
- Key role of kisspeptins, neurokinin B and substance P in GnRH secretion – FSH/LH
- Estrogens, progesterone, androgens direct effect on gonadotrophs, indirect through GnRH
  - Estrogens (-) inhibition of transcription ( $\alpha$ )
  - Kisspeptin stimulation of LH/FSH, GnRH
  - Estrogens (+) shift
  - Progesterone (-) influences pulsatile secretion of GnRH
  - Testosterone, estradiol (-) males, kisspeptin neurons and AR
- GnRHR Ca<sup>2+</sup> mobilization
- Different half-life for circulating LH and FSH



## FSH and LH functions

#### FEMALES

- FSH
  - Growth and development of follicular cell (maturation)
  - Biosynthesis of estradiol
  - Regulation of inhibin synthesis during follicular phase
  - Upregulation of LH receptors (preovulatory follicles)
  - Selection of dominant follicle
  - Recruitment of follicles for next cycle
- LH
  - Stimulation of estrogen synthesis (theca)
  - Oocyte maturation (preovulatory follicle)
  - Rupture of ovulatory follicle, ovulation
  - Conversion of follicle wall to corpus luteum

#### MALES

- LH
  - Intratesticular synthesis of testosterone (Leydig cells)
- FSH
  - Spermatogenesis (Sertoli cells)

#### **Clinical significance**

- Possible deficiency of gonadotropins
- Hypogonadotropic hypogonadism
- Kallmann syndrome
- Syndrome Prader-Willi
- Reproductive dysfunction

## Activins and inhibins


- Inhibins dimeric peptides ( $\alpha$  + 1 or two  $\beta_A$  or  $\beta_B$ )
  - inhibin A dominant follicle, corpus luteum
  - inhibin B testes, luteal and early follicular phase of MC
  - FSH inhibition

#### Activins

- dimeric peptides dimers of  $\beta$  subunits
- FSH stimulation
- autocrine/paracrine factors
- other tissues growth and differentiation

#### Folllistatin

- monomeric polypeptide
- FSH inhibition
- "supplementary" regulation of FSH and LH secretion



# Hormones of hypothalamus secreted by neurohypophysis

## Neurohypophysis


Synthesis - magnocellular neurons (SON, PVN)

Precursor protein (signal peptide, hormone, neurophysin 2, glycopeptide copeptin)


Posttranslational modification – ADH/OT + neurophysins + copeptin

Neurophysins – importance – ADH transport and secretion

Termination (neurohypophysis, eminentia mediana) Secretion – voltage-gated Ca<sup>2+</sup> channels Circulation – free, elimination – kidneys, liver



### Oxytocin



Characteristics

- Mechanoreceptors/tactile receptors
  - endogenous opioids, NO, GABA (-)
  - Prolactin, relaxin (-), Estrogens (+)
- Works together with prolactin and sex hormones

#### Functions

- Lactation (under 1 min)
- Childbirth
  - rhythmical contractions of smooth muscles (gapjunction, stimulation of prostaglandin synthesis – extracellular matrix)
  - postpartum bleeding, uterus involution
- Ejaculation (males)
- Behavior

#### Other functions and places of synthesis

- CNS
  - Stimulation of ACTH secretion through CRH
  - Stimulation of ADH/induced vasoconstriction
  - Stimulation of prolactin secretion
  - Memory traces recollection inhibition
  - Maternal behavior

#### **Clinical significance**

Oxytocin analogues

## Antidiuretic hormone (ADH, vasopresin, AVP)

#### Characteristics


- receptors (G protein)
  - $V_1R V_{1a}(G_{q/11})$  liver, smooth muscles, CNS, adrenal glands only ligand ADH
  - V<sub>2</sub>R (G<sub>s</sub>) kidneys
  - V<sub>3</sub>R V<sub>1b</sub> (G<sub>q/11</sub>) corticotropic cells (CNS), kidneys, thymus, heart, lungs, pancreas, uterus

#### Function

- Water reabsorption (distal tubule, collecting tubule) tubular system with different water permeability in different parts
  - AQP1 proximal tubule, HL descending limb HK 90 % of water reabsorption
  - AQP2 collecting tubule (only ADH; acute X chronic effect)
  - AQP3, AQP4
- Vasoconstriction (hemorrhagic shock, sepsis)


Other functions and places of synthesis

- CNS increased recollection of memory traces
- Periphery stimulation production of factor VIII and von Willebrand factor




## ADH - regulation of secretion

- Osmotic regulation
- Regulation volume-pressure
- Predominantly inhibitory effect of R on magnocellular N



ADH is the main hormone regulating water homeostasis and osmolality, RAAS is the main regulatory system of blood volume and pressure.



## ADH – clinical aspects

#### **Diabetes insipidus (DI)**

- Primary polydipsia
- Decreased ADH synthesis/secretion (ADH gene) (neurogenic)
- Decreased kidney sensitivity (nephrogenic)

#### SIADH – Syndrome of Inappropriate Antidiuretic Hormone Secretion

- Increased ADH synthesis/secretion
- Absence of physiological ADH secretion stimuli

**Absence of thirst after osmotic stimulation** 

#### **Ethanol lowers ADH secretion**

